Table 2.
Summary of TEAEs by IgG Ab status, and NAb status.
| Description, n (%) | Antibody status |
||||
|---|---|---|---|---|---|
| Overall | Ab + | Ab − | NAb + | NAb − | |
| (N = 26) | (n = 13) | (n = 13) | (n = 9) | (n = 17) | |
| No AE | 1 (3.8) | 1 (7.7) | 0 | 1 (11.1) | 0 |
| Any AE | 25 (96.2) | 12 (92.3) | 13 (100.0) | 8 (88.9) | 17 (100.0) |
| Deaths | 2 (7.7) | 2 (15.4) | 0 | 2 (22.2) | 0 |
| Discontinued due to an AE | 2 (7.7) | 2 (15.4) | 0 | 2 (22.2) | 0 |
| Adverse drug reaction | 9 (34.6) | 5 (38.5) | 4 (30.8) | 4 (44.4) | 5 (29.4) |
| SAE | 16 (61.5) | 9 (69.2) | 7 (53.8) | 8 (88.9) | 8 (47.1) |
| Severe or life-threatening AE | 12 (46.2) | 7 (53.8) | 5 (38.5) | 7 (77.8) | 5 (29.4) |
| IRAE | 9 (34.6) | 5 (38.5) | 4 (30.8) | 4 (44.4) | 5 (29.4) |
Ab, antibody; Ab +, antibody positive; Ab −, antibody negative; AE, adverse event; IRAE, infusion-related adverse event; NAb +, neutralizing antibody positive; NAb −, neutralizing antibody negative; SAE, serious adverse event; TEAE, treatment-emergent adverse event.